BioMarin Pharmaceutical | BMRN - Current Assets

Stock Price
51.81
Daily Change
-1.43 -2.69%
Monthly
-4.23%
Yearly
-12.59%
Q2 Forecast
52.94

BioMarin Pharmaceutical reported $4.61B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Moderna USD 5.77B 774M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026